Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
Armin RashidiMaryam EbadiTauseef Ur RehmanHeba ElhusseiniDavid KazadiHossam HalaweishMohammad Haneef KhanAndrea HoeschenQing CaoXianghua LuoAmanda J KabageSharon LopezShernan G HoltanDaniel J WeisdorfAlexander KhorutsChristopher M StaleyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
In allogeneic HCT recipients and patients with AML, third-party FMT was safe and ameliorated intestinal dysbiosis, but did not decrease infections. Novel findings from this trial will inform future development of FMT trials.
Keyphrases
- placebo controlled
- phase iii
- double blind
- stem cell transplantation
- phase ii
- acute myeloid leukemia
- open label
- clinical trial
- study protocol
- bone marrow
- hematopoietic stem cell
- high dose
- allogeneic hematopoietic stem cell transplantation
- current status
- randomized controlled trial
- kidney transplantation
- mesenchymal stem cells